Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

All Drugs and Chemicals

Antineoplastic Agents

Amino Acids

Antibodies

Antibodies, Monoclonal

Docetaxel

Apatinib

Cisplatin

Immunomodulating Agents

Immunoglobulins

Endothelial Growth Factors

Mitogens

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.

SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.

Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.

Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

SHR-1210

The IMRT or VMAT technique was used in our study.

IMRT or VMAT

Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.

Ping Wang, M. D.

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

A Single Arm Exploratory Study of Chemotherapy Plus Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas

Incidence of Treatment-Emergent Adverse Events

Jiangsu HengRui Medicine Co., Ltd.

Tianjin Medical University Cancer Institute and Hospital

Immune Checkpoint Inhibitors

Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.

Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.

Camrelizumab

75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.

66-70 Gy given in 33-35 fractions over 6-7 weeks.

Yan Li, MD, PhD

Xingchen Peng, MD,PhD

Yan Li, MD,PhD

The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

A Phase II Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced, Unresectable Head and Neck Squamous Cell Carcinoma

The number of participants with radiologically confrmed complete or partial response according to RECIST 1.1

OS is the time from randomization to death due to any cause.

DFS is the time from the date of randomization to the date of first record of disease recurrence or death.

The number of participants who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC	NCT03671265	Esophageal Canc...	SHR-1210 IMRT or VMAT Apatinib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer	NCT04405154	Head and Neck N...	Camrelizumab Cisplatin IMRT or VMAT	18 Years - 75 Years	West China Hospital

Spots Global Cancer Trial Database for imrt or vmat

Every month we try and update this database with for imrt or vmat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.